Added to YB: 2026-03-09
Pitch date: 2026-03-06
LQDA [neutral]
Liquidia Corporation
+5.1%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$3.3B
Pitch Price
$35.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-67.11
P/E
-46.59
EV/Sales
20.81
Sector
Pharmaceuticals
Category
growth
Solid Q4 Results From Liquidia
LQDA (earnings): Q4 confirmed momentum w/ Feb patient starts matching Q4 trajectory. Mgmt reiterated $1B rev by 2027 (vs $148M in 2025), taking share from United Therapeutics (25% patients switching). Trades <5x 2027 FCF (~$600M) vs $2.8B mkt cap. Risks: legal ruling (20% chance), 2027-8 competition.
Read full article (2 min)